2,923 Shares in Biogen Inc. $BIIB Purchased by State of Wyoming

State of Wyoming acquired a new position in Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,923 shares of the biotechnology company’s stock, valued at approximately $632,000.

Other institutional investors have also bought and sold shares of the company. Rothschild Investment LLC lifted its position in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 56 shares during the last quarter. Meeder Advisory Services Inc. boosted its stake in Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after purchasing an additional 57 shares during the period. Kera Capital Partners Inc. grew its holdings in Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after buying an additional 65 shares during the period. Finally, Itau Unibanco Holding S.A. lifted its holdings in shares of Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $209.83 on Monday. The company’s fifty day moving average price is $203.76 and its 200-day moving average price is $193.24. The firm has a market capitalization of $31.00 billion, a price-to-earnings ratio of 37.14, a PEG ratio of 6.48 and a beta of 0.17. Biogen Inc. has a one year low of $131.52 and a one year high of $219.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the previous year, the firm posted $5.47 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 12.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on BIIB shares. Canaccord Genuity Group boosted their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Piper Sandler reiterated an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. Mizuho raised their price target on shares of Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Finally, Royal Bank Of Canada decreased their price target on shares of Biogen from $242.00 to $240.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $227.07.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.